GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Median Diagnostics Inc (XKRX:233250) » Definitions » Debt-to-EBITDA

Median Diagnostics (XKRX:233250) Debt-to-EBITDA : 0.86 (As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Median Diagnostics Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Median Diagnostics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₩692 Mil. Median Diagnostics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₩521 Mil. Median Diagnostics's annualized EBITDA for the quarter that ended in Dec. 2024 was ₩1,406 Mil. Median Diagnostics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 was 0.86.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Median Diagnostics's Debt-to-EBITDA or its related term are showing as below:

XKRX:233250' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -12.08   Med: 0.27   Max: 5.8
Current: 0.86

During the past 10 years, the highest Debt-to-EBITDA Ratio of Median Diagnostics was 5.80. The lowest was -12.08. And the median was 0.27.

XKRX:233250's Debt-to-EBITDA is ranked better than
63.29% of 681 companies
in the Drug Manufacturers industry
Industry Median: 1.62 vs XKRX:233250: 0.86

Median Diagnostics Debt-to-EBITDA Historical Data

The historical data trend for Median Diagnostics's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Median Diagnostics Debt-to-EBITDA Chart

Median Diagnostics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.21 0.30 1.53 -1.79 0.86

Median Diagnostics Semi-Annual Data
Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.21 0.30 1.53 -1.79 0.86

Competitive Comparison of Median Diagnostics's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Median Diagnostics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Median Diagnostics's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Median Diagnostics's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Median Diagnostics's Debt-to-EBITDA falls into.


;
;

Median Diagnostics Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Median Diagnostics's Debt-to-EBITDA for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(692.46 + 520.959) / 1406.281
=0.86

Median Diagnostics's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(692.46 + 520.959) / 1406.281
=0.86

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is one times the quarterly (Dec. 2024) EBITDA data.


Median Diagnostics  (XKRX:233250) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Median Diagnostics Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Median Diagnostics's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Median Diagnostics Business Description

Traded in Other Exchanges
N/A
Address
878 Seoul Office, Dongnae-dong, Kangwon-do, Chuncheon, KOR, 200-883
Median Diagnostics Inc is a Korea based company engaged in providing IVD solutions and veterinary diagnostics services. Its solutions portfolio covers avian influenza diagnosis solution, foot and mouth disease diagnosis solution, African Pig fever solution and others. The company offers ELISA diagnostic products, rapid test kit, molecular diagnosis products, standard diagnosis products and biologicals.

Median Diagnostics Headlines

No Headlines